Pharmiweb.com RSS Feeds 
PharmiWeb Candidate Blog
Features
07 Feb 11
If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting.
However, it’s not really that hard, and with a bit of thought, you will soon be asking why you didn’t do it years ago.
Mike Wood
06 Jan 11
At times of global economic downtown, and internal restructuring within firms, risks to innovation arise. And as businesses look for savings, research and development is seldom exempt.
Max Golby
02 Dec 10
As a result of a vote taken in the European Parliament earlier this week, patients in the European Union will receive improved information on prescription drugs, in addition to being protected from some of the more potentially exploitable clauses of the Commission’s proposed Directive on Information to Patients.
Max Golby
25 Nov 10
In an age of competition and choice, patient knowledge is paramount. Between 1997 and 2007, the Blair government’s entire programme of public sector reforms were delivered under the banner of ‘Choice and Competition’.
Max Golby
22 Nov 10
With the global economy remaining stagnant, big pharma companies are keen to develop blockbuster drugs that have a high financial ceiling. Rodger McMillan, VP of R&D at Astra Zeneca has said that “big pharma is a cash-rich industry – it has to be,” namely because of the huge costs in developing new drugs – sometimes as much as $200 million.
Daniel Reinhold-Shor
18 Nov 10
In the USA alone, when your neighbor is out of work it is a slowdown, when your
family member is added it becomes recession and when you too join the same line
than it surely becomes a depression. The unofficial employment in USA being claimed at 15-25 percent while the economical turnaround seems a mirage; the closer you get the clearer becomes the reality, nothing but refractions.
Naseem Javed
16 Nov 10
In many ways, the National Institute for Health and Clinical Excellence (NICE) embodies many of the characteristics that define the NHS. In a system of universal access — and in a world where resources are finite — tough decisions inevitably have to be made. And by taking difficult decisions, particularly in reference to end of life care, NICE attempts to make the most of the drugs budget we do have.
Max Golby
12 Nov 10
Epratuzumab, a new humanised IgG1 monoclonal antibody that acts on CD22 (a molecule preventing over-activation of the immune system and emergence of auto-immune diseases) has shown promise as a potential treatment of moderate to severe systemic lupus erythematosus (SLE) according to results of a new study EMBLEM.
Olwen Glynn Owen
11 Nov 10
Large pharma has been seeking new biomarkers for years – all part of their drug discovery process, but often only as an afterthought in the development process. That’s changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small -to -medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.
Daniel Reinhold-Shor
04 Nov 10
Most pharmacologists will acknowledge that nutrition is important for good health and well-being, however, at the same time it is also considered to be a chemical nightmare with unknown effects. This has not always been the case, in the past connections between pharmacology and nutrition has been more intimate, as Hippocrates once stated, ‘‘Let food be thy medicine and let medicine be thy food.
Johan Garssen, PhD, Conference Chairman
03 Nov 10
Reshaping the pharmaceutical industry's quality standards is currently the top priority for the Chinese government. Earlier announcements by its Ministry of Health to issue new tougher Good Manufacturing Processes (GMP) standards for medical products comes at the right time as current regulations do not meet international standards which result in poor performance by Chinese companies in the international market.
Emma Naylor
27 Oct 10
Now more than ever, alternative science and holistic remedies are playing a role in our lifestyles. But is that right? Over the past year, we've reported on everything from homeopathy to hypnotherapy. Importantly, we've differentiated between those approaches with at least a modicum of evidence to support them, and those without almost any at all. Yet in contrast to homeopathy, perhaps it can be said that our next target has at least a little science to support it.
Max Golby
20 Oct 10
Last week Pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills. The drug, Fresenius Kabi’s Anastrozole, was made by the German company’s subsidiary in India. The ingredient mix up led to the voluntary recall of 7,192 bottles, each containing 30 tablets.
Emma Naylor- NG Online
19 Oct 10
HealthcarePromotions.co.uk was created to provide UK healthcare professionals and students with a website for all their health promotion resources and news.
James Morgan, Director Healthcare Promotions Ltd
18 Oct 10
As Republican Congressmen line up to attack Barack Obama’s landmark U.S. healthcare reforms ahead of next month’s mid-term elections, reforms on this side of the Atlantic are receiving equally forceful criticism.
Max Golby
18 Oct 10
Out there on the branding battlefields its simply do or die as brand images are either hyper visible or mortally lost in oblivion. Commanding success for any idea on the global scene demands universal access on e-commerce that is only deliverable by a cyber name identity, as it's the only key to open the site.
Naseem Javed
08 Oct 10
The Kingdom of Saudi Arabia provides a new opportunity for clinical research, and can open doors to untapped populations, explains Rani Abraham at ClinTec International
Rani Abraham - ClinTec International
08 Oct 10
With access, cost and quality concerns plaguing pharmaceutical delivery systems both in the US as well as globally, the Next Generation Pharmaceutical Drug Discovery committee has been formed to confront, assess and deliver new strategies to secure the future of the industry.
Emma Naylor
29 Sep 10
If you have been looking around for a CV writing service you will have noticed that prices vary considerably and may be wondering why. The CV & Interview Advisors (that’s us) were one of the early entrants into the world of CV writing and have been around for many years.
Matt Craven
29 Sep 10
Over the last few years, many companies have started to offer CV appraisals to the extent that the market is now flooded with offers of free advice. I remember the days when we and one or two other CV writing companies offered such a service and it became a very effective way of building relationships with customers and strutting our expertise on all things CV related.
Matt Craven
29 Sep 10
There has been some conjecture amongst professionals regarding the merits of a personal profile on a CV. This conjecture stems from the fact that many job seekers fill there personal profiles with irrelevant and mostly clichéd information.
Matt Craven
29 Sep 10
In my capacity as a Career Consultant, I have worked closely with freelancers & contractors for many years and two challenges keep rearing their ugly head: Firstly, how does a freelancer write a CV that isn’t six pages long; and secondly, what happens if you want to apply for a role that draws upon skills gained in a contract that isn’t the most recent piece of work that you have done.
Matt Craven
24 Sep 10
In a climate of fiscal hardship, everybody has a special case to plead. Indeed, when the funding scalpel is out, every department and almost every recipient of public sector funds has a special tale to tell. The truth is, science funding really is that important.
Max Golby
20 Sep 10
If you have written material for a journal like this one, or a book, we may be holding monies due to you.
James Davis
16 Sep 10
As healthcare innovation produces new treatments, and new information delivers increased awareness, a substantial rise in prescription drug use is only to be expected. For the most part, this can largely be seen as a positive development.
Max Golby
09 Sep 10
Potentially lifesaving science should not be marginalized to the status of a political football. Yet for so many years in the United States, that’s exactly what stem cell science has become.
Max Golby
07 Sep 10
A new book by Rebecca J. Anderson
Mike Wood
06 Sep 10
Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
Emma Naylor
02 Sep 10
Even in the good years, mental health budgets were seldom in line with what experts expected or deemed necessary. Thus, in times of budget deficits and scathing public expenditure cuts, the worry becomes even greater. For those that care most about the health service then, the Coalition government's decision to ring fence healthcare spending has been largely applauded.
Max Golby
25 Aug 10
Originally born under the Conservatives, but fully evolved under Labour, Private Finance Initiatives (PFIs) essentially offered the NHS an alternative way of paying for new hospitals and renovations at a time when public capital was said to be limited.
Max Golby
